SCOLR Pharma Extends Research Agreement with Consumer Products Company
News Dec 07, 2007
SCOLR Pharma, Inc. has announced an extension of its research agreement with a global consumer products company to co-develop an application of its CDT® drug delivery technology.
Stephen J. Turner, SCOLR’s Vice President and Chief Technical Officer, stated “This extension is a positive indication of the progress we are making with our co-development partner on a novel application of our CDT drug delivery technology. We remain optimistic that if successful, a branded consumer product incorporating our technology could begin commercialization by 2009.”
SCOLR recently announced entering a development and licensing agreement with Dr. Reddy for a cardiopulmonary application of its CDT technology. SCOLR also continues its collaboration with Biocryst to development of an oral application of Biocryst’s peramivir, an anti-viral compound currently in clinical trials as potential intramuscular and intervenous treatments for seasonal and life-threatening influenza.
Under the terms of the agreement, SCOLR will receive a research fee. If the program is successful, it is anticipated that the parties would enter a global license agreement to allow for application of SCOLR’s technology.
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE